Oxycinchophen
Chemical compound
- M01CA03 (WHO)
- 3-Hydroxy-2-phenyl-4-quinolinecarboxylic acid
- 485-89-2
N
- 10239
- 9822
N
- UK6392GD5W
- D07271
Y
- DTXSID0057750
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- O=C(O)c1c3ccccc3nc(c1O)c2ccccc2
InChI
- InChI=1S/C16H11NO3/c18-15-13(16(19)20)11-8-4-5-9-12(11)17-14(15)10-6-2-1-3-7-10/h1-9,18H,(H,19,20)
N
- Key:XAPRFLSJBSXESP-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Oxycinchophen is an antirheumatic agent.[1][2]
References
- ^ Iversen M, Munck J, Schourup K (1953). "On the toxicity of 3-hydroxy-2-phenylcinchoninic acid (oxycinchophen); histo-pathological studies in rabbits and guinea-pigs". Acta Pharmacologica et Toxicologica. 9 (3): 215–9. doi:10.1111/j.1600-0773.1953.tb02948.x. PMID 13123940.
- ^ US 2776290, issued 1957, assigned to Chemo Puro
- v
- t
- e
Specific antirheumatic products / DMARDs (M01C)
- Oxycinchophen
- Sodium aurothiomalate
- Sodium aurothiosulfate
- Auranofin
- Aurothioglucose
- Aurotioprol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e